Prognostic Factors in Myeloma: What They Tell Us About the Pathophysiology of the Disease

References

• Greipp P. R., Katzman J. A., O'Fallon W. M., Kyle R. A. Value of β-microglobulin level and plasma cell labelling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72: 219
   PubMed Web of Science ®Google Scholar
• Boccadoro M., Massaia M., Dianzani U., Pileri A. Multiple myeloma: Biological and clinical significance of bone marrow plasma cell labelling index. Haematologica (Pavia) 1987; 72: 171
   PubMedGoogle Scholar
• Boccadoro M., Gavarotti P., Foscati G. Low plasma cell 3H thymidine incorporation in monoclonal gam-mopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy. Br. J. Haematol. 1984; 58: 689–696
   PubMed Web of Science ®Google Scholar
• Greipp P. R., Witzig T. E., Gonchoroff N. J. Immunofluorescent plasma cell labelling indices (LI) using a monoclonal antibody (BU-1). Am. J. Hematol. 1985; 20: 289–292
   PubMed Web of Science ®Google Scholar
• Boccadoro M., Marmont F., Fossati M., Tribalto G., Re-Doglia V., Battaglio S., Massaia M., Gallamini A., Com-Otti B., Barbui T., et al. Early responder myeloma: kinetic studies identify a patient subgroup characterised by a very poor prognosis. J. Clin. Oncol. 1989; 7: 119–125
   PubMed Web of Science ®Google Scholar
• Kawano M. M., Huang N., Harada H., Harada Y., Sakai A., Tanaka H., Iwato K., Kuramoto A. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood 1993; 82: 564–570
   PubMed Web of Science ®Google Scholar
• Bakkus M. H. C., Heirman C., Van Riet I., Van Camp B., Thielemans K. Evidence that multiple myeloma lg heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992; 80: 2326–2335
   PubMed Web of Science ®Google Scholar
• Ralph Q. M., Brisco M. J., Joshua D. E., Brown R., Gibson J., Morley A. A. Advancement of multiple myeloma from diagnosis through plateau phase to progression does not involve a new B-cell clone: evidence from the lg heavy chain gene. Blood 1993; 82: 202–206
   PubMed Web of Science ®Google Scholar
• Vescio R., Cao J., Kunkel L., Hong C., Schiller G., Lichtenstein A., Newman R., Berenson J. R. Immunoglobulin produced by the malignant cells in multiple myeloma frequently results from an antigenically driven process and the 5′ end of the J segment is often truncated. Proc. IV Int. Workshop in Myeloma, Rochester, MN, 1993; 49
   Google Scholar
• Warburton P., Joshua D. E., Gibson J., Brown R. D. CD10-(CALLA)-positive lymphocytes in myeloma: Evidence that they are a malignant precursor population and are of germinal centre origin. Leukemia and Lymphoma 1989; 1: 11–20
   PubMedGoogle Scholar
• MacLennan I. C. M., Chan E. Y. T. The origin of bone marrow plasma cells. Epidemiology and Biology of Multiple Myeloma, G. I. Abrams, M. Potter. Springer-Verlag, Berlin 1991; 129
   Google Scholar
• Bakkus M. H. C., Van Riet I., Van Camp B., Thiele-Mans K. Evidence that the clonogenic cell in multiple myeloma originates from a pre-switched but somatically mutated B cell. Proc. IV Int. Workshop in Myeloma, Rochester, MN, 1993; 49
   Google Scholar
• Joshua D. E., Snowdon L., Gibson J., Hand H., Brown R., Warburton P., Kulkarni A., Vincent P., Young G., Gatenby P., Basten A., Kronenberg H. Multiple myeloma: plateau phase revisited. Haematologic. Rev. 1991; 5: 59
   Google Scholar
• Simonnsson B., Kallander C. R. F., Brenning G., Killan-Der A., Ahre A. Evaluation of serum thymidine kinase as a marker in multiple myeloma. Br. J. Haematol. 1985; 61: 215–224
   PubMed Web of Science ®Google Scholar
• Brown R. D., Joshua D. E., Ioannidis R., Kronenberg H. Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma. Aust. N. Z. J. Med. 1989; 19: 226–232
   PubMedGoogle Scholar
• Greipp P. R., Lust J. A., O'Fallon W. M., Katzmann J. A., Witzig T. E., Kyle R. A. Plasma cell labelling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382–7
   PubMed Web of Science ®Google Scholar
• Brown R. D., Joshua D. E., Nelson M., Gibson J., Dunn J., MacLennan I. C. M. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V trial. Br. J. Haematol. 1992; 84: 238–241
   Web of Science ®Google Scholar
• Carbone P. P., Kaplan H. S., Mushoff K. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Areci R. J. Clinical significance of p-glycoprotein in multi-drug resistance malignancies. Blood 1993; 81: 2215–2222
   PubMed Web of Science ®Google Scholar
• Sonneveld P., Durie B. G. M., Lokhorst H. M., Marie J. P., Solbu G., Suciu S., Zittoun R., Lowenberg B., Nooter K. Modulation of multi-drug resistant multiple myeloma by cyclosporin. Lancet 1992; 340: 255–59
   PubMed Web of Science ®Google Scholar
• Grogan T., Spier C. M., Salmon S. E., Matzler M., Rybiski J., Weinstein R. S., Scheper R. J., Dalton W. A. S.T. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993; 81: 490–495
   PubMed Web of Science ®Google Scholar
• Pilarski L. M., Mant M. J., Belch A. R. Monoclonal multi-drug resistant circulating cells with DNA hyper-ploidy persist despite chemotherapy and represent a putative malignant stem cell in multiple myeloma. Proc. IV Int. Workshop on Multiple Myeloma, Rochester, MA, 1993; 51–52
   Google Scholar
• Greipp P. R., Raymond N. M., Kyle R. A., O'Fallon W. M. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985; 65: 305
   PubMed Web of Science ®Google Scholar
• Bartl R., Frisch B., Diem H., Mundel M., Nagel D., Lamerz R., Moghadam A. Histologic, biochemical and clinical parameters for monitoring multiple myeloma. Cancer 1991; 68: 2241–2250
   PubMed Web of Science ®Google Scholar
• Bataille R., Durie B. G. M., Geriner J. Serum β2-microglobulin and survival duration in multiple myeloma: a simple, reliable marker for staging. Br. J. Haematol. 1983; 55: 439
   PubMed Web of Science ®Google Scholar
• Durie B. G. M., Stock-Novack D., Salmon S. E. Prognostic value of pretreatment serum β-microglobulin in myeloma. A Southwest Oncology Group study. Blood 1990; 75: 823
   PubMed Web of Science ®Google Scholar
• Greipp P. R., Katzmann J. A., O'Fallon W., Kyle R. A. Value of β-microglobulin level and plasma cell labelling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 72: 219
   PubMed Web of Science ®Google Scholar
• Cuzick J., De Stavola B. L., Coopert E. H., Chapman C., MacLennan I. C. M. Long-term prognostic value of serum beta-2-microglobulin in myelomatosis. Br. J. Haematol. 1990; 33: 101–109
   Web of Science ®Google Scholar
• Van Dobbenburgh O. A., Rodenhuis S., Ockhuizen T., Weltevreden E., Houwen B., Fidler V., Meijer S., Marrink J. Serum beta-2-microglobulin: a real improvement in the management of multiple myeloma?. Br. J. Haematol. 1985; 61: 611–620
   PubMed Web of Science ®Google Scholar
• Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842
   PubMed Web of Science ®Google Scholar
• Merlini G., Gobbi P. G., Ascari E. The Merlini, Waldenstrom, Jayakar staging system revisited. Eur. J. Haematol. 1989; 43: 105
   Web of Science ®Google Scholar
• MacLennan I. C. M., Cooper E. H., Chapman C. E., Kelly K. A., Crockson R. A. Renal failure in myelomatosis. Eur. J. Haematol. 1989; 43: 60–65
   Web of Science ®Google Scholar
• Solomon A., Weiss D., Kaltine A. Nephrototic potential of Bence Jones Proteins. N. Engl. J. Med. 1991; 324: 1845
   PubMed Web of Science ®Google Scholar
• Hirano T. Interleukin 6 (IL-6) and its receptor: their role in plasma cell neoplasia. Int. J. Cell Clon. 1991; 9: 166–184
   PubMedGoogle Scholar
• Klein B., Wijenees J., Zhang X-G, Jourdan M., Boiron J. M., Brochier J., Liautard J., Merlin M., Clement C., Morel-Fournenier B., Lu X. Y., Marmoni P., Sany J., Bataille R. Murine antileukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198–2003
   PubMed Web of Science ®Google Scholar
• Klein B., Bataille R. Cytokine network in human multiple myeloma. Hematol. Oncol. Clin. N. Am. 1992; 6: 273–284
   PubMed Web of Science ®Google Scholar
• Bataille R., Jourdan M., Zhang X. G., et al. Serum levels of Interleukin-6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyspasias. J. Clin. Invest. 1989; 84: 2008
   PubMed Web of Science ®Google Scholar
• Ludwig H., Nachbaur D. M., Fritz E., et al. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 1991; 77: 2794
   PubMed Web of Science ®Google Scholar
• Brown R., Joshua D., Uhr E., Snowdon L., Gibson J. The use of a commercially available immunoassay to determine the level of Interleukin-6 in the serum of patients with myeloma. Leukemia and Lymphoma 1991; 5: 151–155
   PubMed Web of Science ®Google Scholar
• Brown R. D., Snowdon L., Uhr E., Gibson J., Joshua D. E. C-reactive protein (CRP) levels do not reflect disease status in patients with multiple myeloma. Leukemia and Lymphoma 1993; 9: 509–512
   PubMed Web of Science ®Google Scholar
• Greipp P. R. The role of plasma cell labelling index an soluble IL-6 receptor in multiple myeloma. Proc. IV Int. Workshop in Myeloma, Mayo Clinic, Rochester, MN, 1993; 62–63
   Google Scholar
• Omede P., Boccadoro M., Gallaone G., Frieri R., Battaglio S., Redoglia V., Pileri A. Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. Blood 1990; 76: 1375–1379
   PubMed Web of Science ®Google Scholar
• Joshua D. E., Wolf M., Matthews J., Tan L., Sheridan W., Pilkington G., Page F. Peripheral blood lymphocytes surface antigen expression and prognosis in myeloma. Australian leukaemia study group study. Leukemia and Lymphoma 1992, in press
   Web of Science ®Google Scholar
• Cimino G., Avvisati G., Amadori S., Cava M. C., Giannarelli D., Di Nucci G. D., Magliocca V., Petrucci M. T., Poti G., Sgadari C., Mandelli F. High serum IL-2 levels are predictive of prolonged survival in multiple myeloma. Br. J. Haematol. 1990; 75: 373–377
   PubMed Web of Science ®Google Scholar
• Gottlieb D. J., Prentice H. G., Mehta A. B., Galazka A. R., Heslop H. E., Hoffbrand A. V., Brenner M. K. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma. Br. J. Haematol. 1990; 75: 499–505
   PubMed Web of Science ®Google Scholar
• Peest D., Leo R., Hein R., Stannat-Keibling S., Tschechne B., Fett W., Harms P., Hoffman L., Bartl R., Wacker H. H., Gorg S., Atzpodien J., Kirchner H., Deicher H. Low-Dose recombinant interleukin 2 treatment of advanced multiple myeloma patients. Proc. IV Int. Workshop in Myeloma, Rochester, MN, 1993; 49
   Google Scholar